End-ischemic hypothermic oxygenated perfusion for extended criteria donors in liver transplantation: a multicenter, randomized controlled trial-HOPExt.


Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
06 Jun 2023
Historique:
received: 27 03 2023
accepted: 22 05 2023
medline: 8 6 2023
pubmed: 7 6 2023
entrez: 6 6 2023
Statut: epublish

Résumé

Given the scarce donor supply, an increasing number of so-called marginal or extended criteria donor (ECD) organs are used for liver transplantation. These ECD liver grafts are however known to be associated with a higher rate of early allograft dysfunction and primary non-function because of a greater vulnerability to ischemia-reperfusion injury. The end-ischemic hypothermic oxygenated machine perfusion (HOPE) technique may improve outcomes of liver transplantation with ECD grafts by decreasing reperfusion injury. HOPExt trial is a comparative open-label, multicenter, national, prospective, randomized, controlled study, in two parallel groups, using static cold storage, the gold standard procedure, as control. The trial will enroll adult patients on the transplant waiting list for liver failure or liver cirrhosis and/or liver malignancy requiring liver transplantation and receiving an ECD liver graft from a brain-dead donor. In the experimental group, ECD liver grafts will first undergo a classical static cold (4 °C) storage followed by a hypothermic oxygenated perfusion (HOPE) for a period of 1 to 4 h. The control group will consist of the classic static cold storage which is the gold standard procedure in liver transplantation. The primary objective of this trial is to study the efficacy of HOPE used before transplantation of ECD liver grafts from brain-dead donors in reducing postoperative early allograft dysfunction within the first 7 postoperative days compared to simple cold static storage. We present in this protocol all study procedures in regard to the achievement of the HOPExt trial, to prevent biased analysis of trial outcomes and improve the transparency of the trial results. Enrollment of patients in the HOPExt trial has started on September 10, 2019, and is ongoing. ClinicalTrials.gov NCT03929523. Registered on April 29, 2019, before the start of inclusion.

Sections du résumé

BACKGROUND BACKGROUND
Given the scarce donor supply, an increasing number of so-called marginal or extended criteria donor (ECD) organs are used for liver transplantation. These ECD liver grafts are however known to be associated with a higher rate of early allograft dysfunction and primary non-function because of a greater vulnerability to ischemia-reperfusion injury. The end-ischemic hypothermic oxygenated machine perfusion (HOPE) technique may improve outcomes of liver transplantation with ECD grafts by decreasing reperfusion injury.
METHODS METHODS
HOPExt trial is a comparative open-label, multicenter, national, prospective, randomized, controlled study, in two parallel groups, using static cold storage, the gold standard procedure, as control. The trial will enroll adult patients on the transplant waiting list for liver failure or liver cirrhosis and/or liver malignancy requiring liver transplantation and receiving an ECD liver graft from a brain-dead donor. In the experimental group, ECD liver grafts will first undergo a classical static cold (4 °C) storage followed by a hypothermic oxygenated perfusion (HOPE) for a period of 1 to 4 h. The control group will consist of the classic static cold storage which is the gold standard procedure in liver transplantation. The primary objective of this trial is to study the efficacy of HOPE used before transplantation of ECD liver grafts from brain-dead donors in reducing postoperative early allograft dysfunction within the first 7 postoperative days compared to simple cold static storage.
DISCUSSION CONCLUSIONS
We present in this protocol all study procedures in regard to the achievement of the HOPExt trial, to prevent biased analysis of trial outcomes and improve the transparency of the trial results. Enrollment of patients in the HOPExt trial has started on September 10, 2019, and is ongoing.
TRIAL REGISTRATION BACKGROUND
ClinicalTrials.gov NCT03929523. Registered on April 29, 2019, before the start of inclusion.

Identifiants

pubmed: 37280696
doi: 10.1186/s13063-023-07402-0
pii: 10.1186/s13063-023-07402-0
pmc: PMC10243046
doi:

Banques de données

ClinicalTrials.gov
['NCT03929523']

Types de publication

Randomized Controlled Trial Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

379

Subventions

Organisme : PHRCN
ID : PHRCN-18-0053

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2023. The Author(s).

Références

Selzner M, RüDiger HA, Sindram D, Madden J, Clavien PA. Mechanisms of ischemic injury are different in the steatotic and normal rat liver. Hepatology. 2000;32(6):1280–8.
doi: 10.1053/jhep.2000.20528 pubmed: 11093735
Gracia-Sancho J, Casillas-Ramírez A, Peralta C. Molecular pathways in protecting the liver from ischaemia/reperfusion injury: a 2015 update. Clin Sci. 2015;129(4):345–62.
doi: 10.1042/CS20150223
Barshes NR, Horwitz IB, Franzini L, Vierling JM, Goss JA. Waitlist mortality decreases with increased use of extended criteria donor liver grafts at adult liver transplant centers. Am J Transplant. 2007;7(5):1265–70.
doi: 10.1111/j.1600-6143.2007.01758.x pubmed: 17359503
Howard TK, Klintmalm GBG, Cofer JB, Husberg BS, Goldstein RM, Gonwa TA. The influence of preservation injury on rejection in the hepatic transplant recipient. Transplantation. 1990;49(1):103–6.
doi: 10.1097/00007890-199001000-00023 pubmed: 2300999
Croome KP, Hernandez-Alejandro R, Chandok N. Early allograft dysfunction is associated with excess resource utilization after liver transplantation. Transplant Proc. 2013;45(1):259–64.
doi: 10.1016/j.transproceed.2012.07.147 pubmed: 23375312
Deschenes M, Belle SH, Krom RAF, Zetterman RK, Lake JR. Early allograft dysfunction after liver transplantation: a definition and predictors of outcome. Transplantation. 1998;66(3):302–10.
doi: 10.1097/00007890-199808150-00005 pubmed: 9721797
Olthoff KM, Kulik L, Samstein B, Kaminski M, Abecassis M, Emond J, et al. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl. 2010;16(8):943–9.
doi: 10.1002/lt.22091 pubmed: 20677285
Salvalaggio P, Afonso RC, Felga G, Ferraz-Neto BH. Uma proposta para graduar a gravidade de disfunção precoce do enxerto após o transplante de fígado. Einstein São Paulo. 2013;11(1):23–31.
doi: 10.1590/S1679-45082013000100006 pubmed: 23579740 pmcid: 4872964
Briceño J, Ciria R. Early graft dysfunction after liver transplantation. Transplant Proc. 2010;42(2):631–3.
doi: 10.1016/j.transproceed.2010.02.004 pubmed: 20304210
Pokorny H, Gruenberger T, Soliman T, Rockenschaub S, Längle F, Steininger R. Organ survival after primary dysfunction of liver grafts in clinical orthotopic liver transplantation. Transpl Int. 2000;13:S154–7.
doi: 10.1007/s001470050310 pubmed: 11111986
Karangwa SA, Dutkowski P, Fontes P, Friend PJ, Guarrera JV, Markmann JF, et al. Machine perfusion of donor livers for transplantation: a proposal for standardized nomenclature and reporting guidelines. Am J Transplant. 2016;16(10):2932–42.
doi: 10.1111/ajt.13843 pubmed: 27129409 pmcid: 5132023
Schön MR, Kollmar O, Wolf S, Schrem H, Matthes M, Akkoc N, et al. Liver Transplantation after organ preservation with normothermic extracorporeal perfusion. Ann Surg. 2001;233(1):114–23.
doi: 10.1097/00000658-200101000-00017 pubmed: 11141233 pmcid: 1421174
van der Plaats A, Maathuis MHJ, ’t Hart NA, Bellekom AA, Hofker HS, van der Houwen EB, et al. The Groningen hypothermic liver perfusion pump: functional evaluation of a new machine perfusion system. Ann Biomed Eng. 2006;34(12):1924–34.
doi: 10.1007/s10439-006-9207-4 pubmed: 17066322
Schlegel A, Kron P, Dutkowski P. Hypothermic machine perfusion in liver transplantation. Curr Opin Organ Transplant. 2016;21(3):308–14.
doi: 10.1097/MOT.0000000000000303 pubmed: 26918882
Dutkowski P, Polak WG, Muiesan P, Schlegel A, Verhoeven CJ, Scalera I, et al. First comparison of hypothermic oxygenated perfusion versus static cold storage of human donation after cardiac death liver transplants: an international-matched case analysis. Ann Surg. 2015;262(5):764–71.
doi: 10.1097/SLA.0000000000001473 pubmed: 26583664
van Rijn R, Schurink IJ, de Vries Y, van den Berg AP, Cortes Cerisuelo M, Darwish Murad S, et al. Hypothermic machine perfusion in liver transplantation — a randomized trial. N Engl J Med. 2021;384(15):1391–401.
doi: 10.1056/NEJMoa2031532 pubmed: 33626248
Czigany Z, Pratschke J, Froněk J, Guba M, Schöning W, Raptis DA, et al. Hypothermic oxygenated machine perfusion reduces early allograft injury and improves post-transplant outcomes in extended criteria donation liver transplantation from donation after brain death: results from a multicenter randomized controlled trial (HOPE ECD-DBD). Ann Surg. 2021;274(5):705–12.
doi: 10.1097/SLA.0000000000005110 pubmed: 34334635
Ravaioli M, Germinario G, Dajti G, Sessa M, Vasuri F, Siniscalchi A, et al. Hypothermic oxygenated perfusion in extended criteria donor liver transplantation—a randomized clinical trial. Am J Transplant. 2022;22(10):2401–8.
doi: 10.1111/ajt.17115 pubmed: 35671067 pmcid: 9796786
Slankamenac K, Graf R, Barkun J, Puhan MA, Clavien PA. The comprehensive complication index: a novel continuous scale to measure surgical morbidity. Ann Surg. 2013;258(1):1–7.
doi: 10.1097/SLA.0b013e318296c732 pubmed: 23728278
Guarrera JV, Henry SD, Samstein B, Reznik E, Musat C, Lukose TI, et al. Hypothermic machine preservation facilitates successful transplantation of “orphan” extended criteria donor livers: machine preservation of ECD livers. Am J Transplant. 2015;15(1):161–9.
doi: 10.1111/ajt.12958 pubmed: 25521639
Uniform Requirements for Manuscripts Submitted to Biomedical Journals. N Engl J Med. 1997;336(4):309–16. https://doi.org/10.1056/NEJM199701233360422 .
Schlegel A, Mueller M, Muller X, Eden J, Panconesi R, von Felten S, et al. A multicenter randomized-controlled trial of hypothermic oxygenated perfusion (HOPE) for human liver grafts before transplantation. J Hepatol. 2023;78(4):783–93. https://doi.org/10.1016/j.jhep.2022.12.030 .
doi: 10.1016/j.jhep.2022.12.030 pubmed: 36681160
Antoine C, Jasseron C, Dondero F, Savier E, the French National Steering Committee of Donors After Circulatory Death. Liver transplantation from controlled donors after circulatory death using normothermic regional perfusion: an initial French experience. Liver Transpl. 2020;26(11):1516–21.
doi: 10.1002/lt.25818 pubmed: 32531132
Czigany Z, Schöning W, Ulmer TF, Bednarsch J, Amygdalos I, Cramer T, et al. Hypothermic oxygenated machine perfusion (HOPE) for orthotopic liver transplantation of human liver allografts from extended criteria donors (ECD) in donation after brain death (DBD): a prospective multicentre randomised controlled trial (HOPE ECD-DBD). BMJ Open. 2017;7(10):e017558.
doi: 10.1136/bmjopen-2017-017558 pubmed: 29018070 pmcid: 5652559

Auteurs

Pierre Pradat (P)

Centre for Clinical Research, Hospices Civils de Lyon, Croix-Rousse University Hospital, Lyon, France. pierre.pradat@univ-lyon1.fr.

Solene Pantel (S)

Centre for Clinical Research, Hospices Civils de Lyon, Croix-Rousse University Hospital, Lyon, France.

Marianne Maynard (M)

Centre for Clinical Research, Hospices Civils de Lyon, Croix-Rousse University Hospital, Lyon, France.

Laure Lalande (L)

Department of Pharmacy, Croix-Rousse University Hospital, Hospices Civils de Lyon, Lyon, France.

Sylvie Thevenon (S)

Centre for Clinical Research, Hospices Civils de Lyon, Croix-Rousse University Hospital, Lyon, France.

Rene Adam (R)

Department of HPB Surgery and Liver Transplantation, Paul Brousse University Hospital, Villejuif, France.

Marc-Antoine Allard (MA)

Department of HPB Surgery and Liver Transplantation, Paul Brousse University Hospital, Villejuif, France.

Fabien Robin (F)

Department of HPB Surgery and Liver Transplantation, Pontchaillou University Hospital, Rennes, France.

Michel Rayar (M)

Department of HPB Surgery and Liver Transplantation, Pontchaillou University Hospital, Rennes, France.

Emmanuel Boleslawski (E)

Department of HPB Surgery and Liver Transplantation, Claude Huriez University Hospital, Lille, France.

Olivier Scatton (O)

Department of HPB Surgery and Liver Transplantation, Pitié Salpêtrière Hospital, Paris, France.

Mircea Chirica (M)

Department of HPB Surgery and Liver Transplantation, Michallon University Hospital, Grenoble, France.

François Faitot (F)

Department of HPB Surgery and Liver Transplantation, Hautepierre University Hospital, Strasbourg, France.

Philippe Bachellier (P)

Department of HPB Surgery and Liver Transplantation, Hautepierre University Hospital, Strasbourg, France.

Olivier Soubrane (O)

Department of HPB Surgery and Liver Transplantation, Beaujon University Hospital, Clichy, France.

Kayvan Mohkam (K)

Department of Digestive Surgery and Liver Transplantation, Croix-Rousse University Hospital, Hospices Civils de Lyon, Lyon, France.

Jean-Yves Mabrut (JY)

Department of Digestive Surgery and Liver Transplantation, Croix-Rousse University Hospital, Hospices Civils de Lyon, Lyon, France.

Mickaël Lesurtel (M)

Department of Digestive Surgery and Liver Transplantation, Croix-Rousse University Hospital, Hospices Civils de Lyon, Lyon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH